🔗 Share this article

While America proceeds with unprecedented adjustments to its vaccine guidelines, a particular individual appears in a surprising turn: Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on Covid vaccines during the global health crisis and has focused upon alleged deaths after COVID-19 vaccination in her short time at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Health officials had intended to unveil radical revisions to the childhood vaccination calendar recently, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would put the US out of alignment with much of the global community with no evidence for improved outcomes. The announcement has been delayed until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the event. She was just designated interim head of the FDA’s CDER, the fifth appointee to run the center this calendar year.

Consolidating Power at the Agency

The acting appointment could signify a strengthened alliance between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain pediatric immunization guidelines in the US so as to align more like the Danish model, a society with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

To date comments, she has kept her attention on vaccines – usually the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no obvious experience in medication creation, approval processes or management, which has been standard for previous directors of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, stated Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in leading a large organization. She is not an expert in drug approvals.”

Former directors of CBER would “grasp legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that former directors who headed CBER have had.”

This division has an immense workload at the FDA, she stated.

“The public just zeroes in on the new drug program, but the off-patent medication office approves numerous off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and so forth, and all of those must be managed,” Dr. Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant management element to the role, which manages over 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” she said.

Agency Reaction and Controversial Initiatives

In response to questions about Høeg’s qualifications and whether this selection represents more teamwork among agency officials on immunizations, a spokesperson said that the “inquiries stem from incorrect assumptions”.

“Her experience matches the responsibilities of her role,” the spokesperson said, citing the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious rapid medication authorization process that reportedly worried her predecessors. “By what process are these therapies being selected for this fast-track system? Who takes the decisions?” Dr. Howard asked. “There’s a lot of secrecy happening at the FDA right now.”

In general, he said, “the agency looks to be trending towards more relaxed regulations of all drugs, with the exception of immunizations.”

Documented History on Vaccines

With immunizations, Høeg has a more documented, if concerning, track record, some experts said. She authored a research paper using unverified public submissions to estimate the incidence of myocarditis following COVID-19 immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the incoming administration encompassed revising rules for new vaccines and halting “non-essential” immunizations, she said following the vote on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of excluding young men from obtaining COVID-19 vaccinations.

“She is an thorough ideologue who starts off with her preconceived notions and works backwards to retrofit the evidence in a highly deceptive, dishonest way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow contrarians, {like|